Grunenthal Says Actavis, Alkem Infringed Painkiller IP

Law360, New York (July 26, 2013, 6:34 PM ET) -- German pharmaceuticals giant Grunenthal GmbH accused rivals Actavis Inc. and Alkem Laboratories Ltd. of infringing patents for its painkiller Nucynta by seeking federal approval for generic copies of the drug, according to a suit filed in New Jersey federal court Thursday.

Actavis and Alkem allegedly violated the three patents by filing abbreviated new drug applications with the U.S. Food and Drug Administration to manufacture and sell tapentadol hydrochloride tablets for pain management before the patents' expiration, Grunenthal said

The generic pharmaceuticals manufacturers have "committed or aided,...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required

Case Information

Case Title

JANSSEN PHARMACEUTICALS, INC. et al v. ACTAVIS ELIZABETH LLC et al

Case Number

2:13-cv-04507

Court

New Jersey

Nature of Suit

Patent

Judge

Claire C. Cecchi

Date Filed

July 25, 2013

Sections

Law Firms Mentioned

Companies Mentioned

Government Agencies Mentioned